Literature DB >> 24154498

[Treatment of gastric cancer].

F Lordick1, A Hoffmeister.   

Abstract

From a global perspective, gastric cancer including adenocarcinoma of the esophagogastric junction is the fourth most common malignant tumor and the second most common cause of cancer-related death. Due to the lack of specific symptoms of early cancer, most gastric cancers are diagnosed in advanced stages. Staging should include high-resolution computed tomography of the thorax, abdomen, and pelvis and documented video-endoscopy and endoscopic ultrasound. In mucosal gastric cancer, endoscopic resection can replace surgical resection. In more advanced stages, perioperative chemotherapy has been established as a standard of care. In the metastatic setting, treatment goals are palliative. Chemotherapy can prolong survival, improve symptoms, and enhance the quality of life. Combination chemotherapy including a platinum salt plus fluoropyrimidine is the standard of care. About 16 % of gastric cancers exhibit overexpression of the growth factor receptor HER2. Trastuzumab has shown to prolong survival when combined with chemotherapy in HER2-positive gastric cancer.

Entities:  

Mesh:

Year:  2014        PMID: 24154498     DOI: 10.1007/s00108-013-3317-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  29 in total

1.  Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw?

Authors:  Florian Lordick
Journal:  Nat Rev Clin Oncol       Date:  2012-05-01       Impact factor: 66.675

2.  [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].

Authors:  M Moehler; S-E Al-Batran; T Andus; M Anthuber; J Arends; D Arnold; D Aust; P Baier; G Baretton; J Bernhardt; H Boeing; E Böhle; C Bokemeyer; J Bornschein; W Budach; E Burmester; K Caca; W A Diemer; C F Dietrich; M Ebert; A Eickhoff; C Ell; J Fahlke; H Feussner; R Fietkau; W Fischbach; W Fleig; M Flentje; H E Gabbert; P R Galle; M Geissler; I Gockel; U Graeven; L Grenacher; S Gross; J T Hartmann; M Heike; V Heinemann; B Herbst; T Herrmann; S Höcht; R D Hofheinz; H Höfler; T Höhler; A H Hölscher; M Horneber; J Hübner; J R Izbicki; R Jakobs; C Jenssen; S Kanzler; M Keller; R Kiesslich; G Klautke; J Körber; B J Krause; C Kuhn; F Kullmann; H Lang; H Link; F Lordick; K Ludwig; M Lutz; R Mahlberg; P Malfertheiner; S Merkel; H Messmann; H-J Meyer; S Mönig; P Piso; S Pistorius; R Porschen; T Rabenstein; P Reichardt; K Ridwelski; C Röcken; I Roetzer; P Rohr; W Schepp; P M Schlag; R M Schmid; H Schmidberger; W-H Schmiegel; H-J Schmoll; G Schuch; C Schuhmacher; K Schütte; W Schwenk; M Selgrad; A Sendler; J Seraphin; T Seufferlein; M Stahl; H Stein; C Stoll; M Stuschke; A Tannapfel; R Tholen; P Thuss-Patience; K Treml; U Vanhoefer; M Vieth; H Vogelsang; D Wagner; U Wedding; A Weimann; H Wilke; C Wittekind
Journal:  Z Gastroenterol       Date:  2011-04-07       Impact factor: 2.000

3.  HER2 in gastric cancer: a biomarker with clinical impact, but not without translational challenges.

Authors:  Florian Lordick
Journal:  Clin Transl Oncol       Date:  2011-09       Impact factor: 3.405

4.  Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography.

Authors:  Sung Wook Hwang; Dong Ho Lee; Sang Hyub Lee; Young Soo Park; Jin Hyeok Hwang; Jin Wook Kim; Sook Hyang Jung; Na Young Kim; Young Hoon Kim; Kyoung Ho Lee; Hyung-Ho Kim; Do Joong Park; Hye Seung Lee; Hyun Chae Jung; In Sung Song
Journal:  J Gastroenterol Hepatol       Date:  2010-03       Impact factor: 4.029

5.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Authors:  Jaffer A Ajani; Wuilbert Rodriguez; Gyorgy Bodoky; Vladimir Moiseyenko; Mikhail Lichinitser; Vera Gorbunova; Ihor Vynnychenko; August Garin; Istvan Lang; Silvia Falcon
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

6.  Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.

Authors:  Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani
Journal:  J Clin Oncol       Date:  2006-11-01       Impact factor: 44.544

7.  Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

Authors:  B Glimelius; K Hoffman; W Graf; U Haglund; O Nyrén; L Påhlman; P O Sjödén
Journal:  Ann Oncol       Date:  1995-03       Impact factor: 32.976

8.  Capecitabine and oxaliplatin for advanced esophagogastric cancer.

Authors:  David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman
Journal:  N Engl J Med       Date:  2008-01-03       Impact factor: 91.245

9.  Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.

Authors:  S Lorenzen; M Hentrich; C Haberl; V Heinemann; T Schuster; T Seroneit; N Roethling; C Peschel; F Lordick
Journal:  Ann Oncol       Date:  2007-07-28       Impact factor: 32.976

10.  Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.

Authors:  S Pyrhönen; T Kuitunen; P Nyandoto; M Kouri
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more
  2 in total

Review 1.  [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management].

Authors:  I Gockel; A Hoffmeister; F Lordick
Journal:  Chirurg       Date:  2015-11       Impact factor: 0.955

2.  Prognostic significance of mRNA expression of CASPs in gastric cancer.

Authors:  Zixiang Wang; Fubiao Ni; Fangyi Yu; Zhonghui Cui; Xiandong Zhu; Jicai Chen
Journal:  Oncol Lett       Date:  2019-09-05       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.